Literature DB >> 18802412

Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.

Cindy M Weinbaum1, Ian Williams, Eric E Mast, Susan A Wang, Lyn Finelli, Annemarie Wasley, Stephanie M Neitzel, John W Ward.   

Abstract

Serologic testing for hepatitis B surface antigen (HBsAg) is the primary way to identify persons with chronic hepatitis B virus (HBV) infection. Testing has been recommended previously for pregnant women, infants born to HBsAg-positive mothers, household contacts and sex partners of HBV-infected persons, persons born in countries with HBsAg prevalence of >/=8%, persons who are the source of blood or body fluid exposures that might warrant postexposure prophylaxis (e.g., needlestick injury to a health-care worker or sexual assault), and persons infected with human immunodeficiency virus. This report updates and expands previous CDC guidelines for HBsAg testing and includes new recommendations for public health evaluation and management for chronically infected persons and their contacts. Routine testing for HBsAg now is recommended for additional populations with HBsAg prevalence of >/=2%: persons born in geographic regions with HBsAg prevalence of >/=2%, men who have sex with men, and injection-drug users. Implementation of these recommendations will require expertise and resources to integrate HBsAg screening in prevention and care settings serving populations recommended for HBsAg testing. This report is intended to serve as a resource for public health officials, organizations, and health-care professionals involved in the development, delivery, and evaluation of prevention and clinical services.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18802412

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  281 in total

Review 1.  Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.

Authors:  Shigeru Kusumoto; Yasuhito Tanaka; Ryuzo Ueda; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2010-10-06       Impact factor: 7.527

2.  Chronic hepatitis B and liver cancer risks among Asian immigrants in New York City: Results from a large, community-based screening, evaluation, and treatment program.

Authors:  Henry J Pollack; Simona C Kwon; Su H Wang; Laura C Wyatt; Chau Trinh-Shevrin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11       Impact factor: 4.254

3.  Viral hepatitis in Hawai'i--differing perspectives.

Authors:  Alan D Tice; Michael Bannan; Kay Bauman; Tarquin Collis; Alba Hall; William Haning; Shoshana Hannemann; C Bradley Hare; Joseph Humphry; Robert Jao; Carroll Leevy; Heather Lusk; Edward Ochoa; Neal Palafox; Nancy Withers; Kenneth Akinaka
Journal:  Hawaii Med J       Date:  2010-04

Review 4.  The management of chronic hepatitis B in Asian Americans.

Authors:  Myron J Tong; Calvin Q Pan; Hie-Won Hann; Kris V Kowdley; Steven-Huy B Han; Albert D Min; Truong-Sinh Leduc
Journal:  Dig Dis Sci       Date:  2011-09-21       Impact factor: 3.199

5.  Raising awareness of viral hepatitis: National Hepatitis Testing Day, May 19.

Authors:  Regina M Benjamin
Journal:  Public Health Rep       Date:  2012 May-Jun       Impact factor: 2.792

Review 6.  When treating cancer, please don't forget hepatitis B.

Authors:  Lindsay Y King; Raymond T Chung
Journal:  Oncologist       Date:  2010-07-20

7.  Understanding the natural history of chronic HBV and HCV infections.

Authors:  David L Thomas; Adrian M Di Bisceglie; Harvey J Alter; Norah A Terrault
Journal:  J Fam Pract       Date:  2010-04       Impact factor: 0.493

8.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

9.  ASCO Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases.

Authors:  Robin T Zon; Michael N Neuss
Journal:  J Oncol Pract       Date:  2010-07       Impact factor: 3.840

10.  Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.

Authors:  Jessica P Hwang; Maria E Suarez-Almazor; Scott B Cantor; Andrea Barbo; Heather Y Lin; Sairah Ahmed; Mariana Chavez-MacGregor; Christian Donato-Santana; Cathy Eng; Alessandra Ferrajoli; Michael J Fisch; Peter McLaughlin; George R Simon; Gabriela Rondon; Elizabeth J Shpall; Anna S Lok
Journal:  Cancer       Date:  2017-05-18       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.